Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 13, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Changes in share interests were reported for three individuals due to the re-investment of dividends paid on July 12, 2007, at a price of $52.64 per share under the Annual Investment Plan feature:
- Dr. JP Garnier: 369.84 shares
- Dr. D Pulman: 19.93 shares
- Mr. D Stout: 303.43 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification regarding director shareholdings.
Investor Verification Points
- Verify the dividend re-investment price of $52.64 per share.
- Confirm the specific share count increases for Dr. JP Garnier, Dr. D Pulman, and Mr. D Stout.
- Note that this filing does not contain financial performance data for the period.